Clinical trial
Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for…
NCT00469014 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00469014 |
|---|---|
| Title | Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia |
| Official title | Busulfan-Fludarabine-Clofarabine With Allogeneic Stem Cell Transplantation for Advanced Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Advanced, Gleevec Refractory Chronic Myeloid Leukemia. A Randomized Phase II Study. |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Collaborators | Genzyme, a Sanofi Company Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myeloid Leukemia |
| Intervention type | Drug, Other |
| Interventions | Clofarabine, Busulfan, Fludarabine, Stem Cell Infusion, Thymoglobulin (ATG), Filgrastim |
| Enrollment | 72 |
| Start date | Sep 1, 2006 |
| Primary completion | Mar 1, 2013 |
| Completion | Mar 1, 2013 |
| First posted | May 4, 2007 |
| Last update posted | Jan 26, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: